Cilo Cybin was established in 2018 with the vision to transform lives through accessible, effective medical cannabis products. As the first entity in South Africa to obtain both medical cannabis cultivation and manufacturing licenses, we are recognised as leaders in the industry in South Africa. Our commitment to scientific research, innovation, and high-quality standards ensures that our products make a genuine impact on users.

Our core focus is on supplying GMP medical cannabis products, including GMP CBD, CBG, CBN isolates and GMP THC and CBD distillates, to meet the highest standards of quality, effectiveness, care, and safety. Our state-of-the-art indoor cultivation facility is GACP accredited and certified for Good Manufacturing Practices (cGMP). This ensures that our products adhere to stringent international standards, making us a trusted supplier in the medical cannabis space.

We specialise in supplying medical-grade cannabis flower and final products, using a cold ethanol extraction process with high-quality input materials. Our vertically integrated approach allows us to control every aspect of production, from cultivation to final product manufacturing.

Our GMP-certified cannabis products are accepted by international regulatory authorities, including the TGA in Australia, PMDA in Japan, and SAHPRA in South Africa, ensuring compliance with global standards. Our CBD, CBG, CBN isolates, and THC and CBD distillates can be used in various applications such as vape products, tinctures, edibles, and topicals.

Cilo Cybin is dedicated to bringing medical cannabis products to markets worldwide, including Australia, Japan, Thailand, and other countries recognizing SAHPRA GMP accreditation. Our products offer rapid absorption, precise dosing, and targeted relief, making them ideal for various medical applications.

By adhering to the highest standards of GMP cannabis manufacturing, Cilo Cybin ensures that our medical cannabis products are safe, effective, and reliable, making a genuine difference in the lives of our users.